From the *Department of Medicine (Gastroenterology), The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Biostatistics Center;
†Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD;
‡Division of Hematology/Oncology, Department of Medicine, Moores Center for Personalized Cancer Therapy, University of California, San Diego, La Jolla, CA;
§Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX;
∥David H. Koch Institute for Integrative Cancer Research;
¶Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA;
#Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN;
**Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School;
††Department of Medicine, Brigham & Women's Hospital, Boston, MA; and
‡‡Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Address correspondence to: Anirban Maitra, MBBS, Sheikh Ahmed Center for Pancreatic Cancer Research, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit #1050, Houston, TX 77030 (e-mail: firstname.lastname@example.org).
Michael Goggins, Scott M. Lippman, and Pamela E. Constantinou contributed equally to this work.
This research is supported by a Stand Up To Cancer (SU2C)–Lustgarten Foundation Pancreatic Cancer Interception Translational Cancer Research Grant (grant no. SU2C-AACR-DT25-17). SU2C is a program of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C.
The authors declare no conflict of interest.